C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis

International Urology and Nephrology

Volumn 45, Issue 5, 2013, Pages 1355-1364

  Bastos, Kleyton ^a   Lucarelli, Luis Antonio ^b   De Francesco Daher, Elizabeth ^c   Filho, Roberto Pecoits ^d   Henríquez, Carlos ^e   Espinoza, Beatriz ^f   Villanueva, Ignacio ^g   Schwedt, Emma ^h   Schiavelli, Ruben ⁱ   Correa Rotter, Ricardo ^j  

^a CLINESE Centro de Nefrologia de Sergipe Brazil Medserv   (Brazil)

^b Walter Cantídio Univ Hosp   (Brazil)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^e Centro Medico de Occidente   (Venezuela)

^f Médica sur Fresenius Medical Care   (Mexico)

^g Fundación Leonor Goelkel   (Colombia)

^h Centro de Diálisis Asociación Española   (Uruguay)

ⁱ HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

more..

Author keywords

Anemia; C.E.R.A.; Chronic kidney disease; Hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ALOPECIA; ANEMIA; ARGENTINA; ARTERIOVENOUS FISTULA; ARTERY THROMBOSIS; ARTICLE; BRAZIL; CHILE; CHRONIC KIDNEY DISEASE; COLOMBIA; CONSTIPATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECUADOR; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; INFECTION; INFESTATION; INTERSTITIAL NEPHRITIS; IRON BLOOD LEVEL; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; PERU; PHASE 3 CLINICAL TRIAL; PYELONEPHRITIS; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; URUGUAY; VASCULAR DISEASE; VENEZUELA; WOUND FLUID;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; MEXICO; MIDDLE AGED; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SOUTH AMERICA; TRACE ELEMENTS; YOUNG ADULT;

EID: 84887077965     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0272-3     Document Type: Article

References (25)

1. Leaf DE, Goldfarb DS (2009) Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 75:15-24
2. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH (2009) Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton.) 14:240-246
3. Cueto-Manzano AM (2003) Peritoneal dialysis in Mexico. Kidney Int Suppl 63(Suppl 83):S90-S92
4. Cueto-Manzano AM, Rojas-Campos E (2007) Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit Dial Int 27:142-148
5. Garcia-Garcia G, Briseno-Renteria G, Luquin-Arellan VH, Gao Z, Gill J, Tonelli M (2007) Survival among patients with kidney failure in Jalisco, Mexico. J Am Soc Nephrol 18:1922-1927
6. Paniagua R, Ramos A, Fabian R, Lagunas J, Amato D (2007) Chronic kidney disease and dialysis in Mexico. Perit Dial Int 27:405-409
7. Pecoits-Filho R, Abensur H, Cueto-Manzano AM, Dominguez J, vino Filho JC, Fernandez-Cean J et al (2007) Overview of peritoneal dialysis in Latin America. Perit Dial Int 27:316-321
8. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl 2):ii1-ii47
9. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT et al (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712
10. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P et al (2006) Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 1:1211-1215
11. Ebben JP, Gilbertson DT, Foley RN, Collins AJ (2006) Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1:1205-1210
12. Roche (2006) RO0503821 (Methoxy polyethylene glycol-epoetin beta) investigator's brochure
13. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI (2007) Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18:3164-3170
14. Fishbane S, Berns JS (2005) Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68:1337-1343
15. Vaziri ND, Zhou XJ (2009) Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24:1082-1088
16. KDOQI (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50:471-530
17. Munoz M, Villar I, Garcia-Erce JA (2009) An update on iron physiology. World J Gastroenterol 15:4617-4626
18. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B et al (2010) Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 25:4009-4017
19. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE et al (2007) Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 370:1415-1421
20. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC et al (2007) Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 23:969-979
21. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K et al (2007) Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2:637-646
22. Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S et al (2008) C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 28:280-289
23. Roche A, Macdougall IC, Walker RG (2009) Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. Curr Med Res Opin 25:2971-2976
24. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F et al (2008) Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23:3654-3661
25. Fliser D, Kleophas W, Dellanna F, Winkler RE, Backs W, Kraatz U et al (2010) Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 26:1083-1089